| Rivaroxaban plus aspirin versus aspirin alone after endovascular revascularization for symptomatic PAD: insights from VOYAGER PAD J Rymer, SS Anand, E Sebastian Debus, LP Haskell, CN Hess, WS Jones, ... Circulation 148 (24), 1919-1928, 2023 | 4 | 2023 |
| Clinical and vascular laboratory evaluation of peripheral arterial disease MR Jaff, WR Hiatt Peripheral arterial disease handbook, 81-94, 2023 | 4 | 2023 |
| Peripheral arterial disease handbook WR Hiatt, J Regensteiner, AT Hirsch CRC Press, 2023 | 6 | 2023 |
| Rivaroxaban plus Aspirin for extended thromboprophylaxis in acutely ill medical patients: insights from the MARINER trial AC Spyropoulos, M Goldin, W Ageno, GW Albers, CG Elliott, WR Hiatt, ... TH Open 6 (03), e177-e183, 2022 | 1 | 2022 |
| Association of bleeding severity with mortality in extended thromboprophylaxis of medically ill patients in the MAGELLAN and MARINER trials AC Spyropoulos, GE Raskob, AT Cohen, W Ageno, JI Weitz, TE Spiro, ... Circulation 145 (19), 1471-1479, 2022 | 9 | 2022 |
| Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial N Govsyeyev, MR Nehler, CCL Wang, S Kavanagh, WR Hiatt, C Long, ... Journal of vascular surgery 75 (2), 660-670. e3, 2022 | 4 | 2022 |
| World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial L Norgren, R North, I Baumgartner, JS Berger, JI Blomster, WR Hiatt, ... Vascular Medicine 27 (1), 21-29, 2022 | 4 | 2022 |
| Effect of anticoagulant therapy for 6 weeks vs 3 months on recurrence and bleeding events in patients younger than 21 years of age with provoked venous thromboembolism: the … NA Goldenberg, JM Kittelson, TC Abshire, M Bonaca, JF Casella, ... Jama 327 (2), 129-137, 2022 | 43 | 2022 |
| Treatment-dose LMWH versus prophylactic/intermediate dose heparins in high-risk COVID-19 inpatients: rationale and design of the HEP-COVID trial M Goldin, D Giannis, W Diab, J Wang, S Khanijo, G Sharifova, M Cohen, ... Thrombosis and Haemostasis 121 (12), 1684-1695, 2021 | 10 | 2021 |
| Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial J Hsia, ST Kavanagh, CW Hopley, I Baumgartner, JS Berger, GR Fowkes, ... Vascular Medicine 26 (6), 608-612, 2021 | | 2021 |
| Safety and effectiveness of paclitaxel drug-coated devices in peripheral artery revascularization: insights from VOYAGER PAD CN Hess, MR Patel, RM Bauersachs, SS Anand, ES Debus, MR Nehler, ... Journal of the American College of Cardiology 78 (18), 1768-1778, 2021 | 22 | 2021 |
| Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older W Ageno, RD Lopes, M Goldin, RD Yusen, GW Albers, GC Elliott, ... Journal of Thrombosis and Haemostasis 19 (11), 2772-2780, 2021 | 5 | 2021 |
| Low-dose rivaroxaban plus aspirin in older patients with peripheral artery disease undergoing acute limb revascularization: insights from the VOYAGER PAD trial MJ Krantz, SE Debus, J Hsia, MR Patel, SS Anand, MR Nehler, CN Hess, ... European Heart Journal 42 (39), 4040-4048, 2021 | 22 | 2021 |
| Effect of rivaroxaban and aspirin in patients with peripheral artery disease undergoing surgical revascularization: insights from the VOYAGER PAD trial ES Debus, MR Nehler, N Govsyeyev, RM Bauersachs, SS Anand, ... Circulation 144 (14), 1104-1116, 2021 | 42 | 2021 |
| Incidence of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization U Desai, A Kharat, CN Hess, D Milentijevic, F Laliberté, P Zuckerman, ... Annals of Vascular Surgery 75, 217-226, 2021 | 11 | 2021 |
| Total ischemic event reduction with rivaroxaban after peripheral arterial revascularization in the VOYAGER PAD trial RM Bauersachs, M Szarek, M Brodmann, I Gudz, ES Debus, MR Nehler, ... Journal of the American College of Cardiology 78 (4), 317-326, 2021 | 43 | 2021 |
| Ankle-brachial index for risk stratification in patients with symptomatic peripheral artery disease with and without prior lower extremity revascularization: observations from … WR Hiatt, CN Hess, MP Bonaca, S Kavanagh, MR Patel, I Baumgartner, ... Circulation: Cardiovascular Interventions 14 (7), e009871, 2021 | 7 | 2021 |
| Effectiveness of blood lipid management in patients with peripheral artery disease CN Hess, CP Cannon, JA Beckman, PP Goodney, MR Patel, WR Hiatt, ... Journal of the American College of Cardiology 77 (24), 3016-3027, 2021 | 28 | 2021 |
| Association of heart failure with outcomes among patients with peripheral artery disease: insights from EUCLID MD Samsky, A Hellkamp, WR Hiatt, FGR Fowkes, I Baumgartner, ... Journal of the American Heart Association 10 (12), e018684, 2021 | 15 | 2021 |
| Diabetes mellitus and risk stratification after peripheral artery revascularization CN Hess, JW Fu, J Gundrum, NM Allen LaPointe, TY Wang, RK Rogers, ... Journal of the American College of Cardiology 77 (22), 2867-2869, 2021 | 4 | 2021 |
